BHC
Bausch Health Companies Inc.
$4.91
+0.10 (+2.08%)
At close · Jul 7
Market Cap
$1.83B
Shares
373,475,644
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10.27B
+6.7%
FY2025
Net Income
$157M
+441.3%
FY2025
Gross Margin
71.27%
-2.1pp
FY2017
Operating Margin
17.66%
+1.6pp
FY2025
Diluted EPS
$0.42
+423.1%
FY2025
Operating Cash Flow
$1.4B
-12.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.53B | $10.27B | $9.63B | $8.76B | $8.12B | $8.43B | $8.03B | $8.6B | $8.38B | $8.72B | $9.67B | $10.45B | $8.21B | $5.77B | $3.48B | $2.43B | $1.18B | $820.43M | $757.18M | |
| $2.43B | — | — | — | — | — | — | — | — | $2.51B | $2.57B | $2.53B | $2.18B | $1.85B | $905.1M | $683.75M | $395.6M | $204.31M | $197.17M | |
| $6.07B | — | — | — | — | — | — | — | — | $6.22B | $7.1B | $7.92B | $6.03B | $3.92B | $2.58B | $1.74B | $785.64M | $616.12M | $560.01M | |
| — | — | — | — | — | — | — | — | — | 71.27% | 73.41% | 75.76% | 73.46% | 68% | 73.99% | 71.83% | 66.51% | 75.1% | 73.96% | |
| $649M | $629M | $616M | $604M | $529M | $465M | $452M | $471M | $413M | $361M | $421M | $334M | $246M | $156.8M | $79.1M | $65.69M | $68.31M | $47.58M | $69.81M | |
| $3.43B | $3.44B | $3.3B | $2.92B | $2.63B | $2.62B | $2.37B | $2.55B | $2.47B | $2.58B | $2.81B | $2.7B | $2.03B | $1.31B | $756.1M | $572.47M | $276.55M | $167.63M | $188.92M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $1.9B | $931.44M | $566.99M | $228.93M | $113.91M | — | |
| — | $1.21B | $1.27B | $1.26B | $1.39B | $1.55B | $1.83B | $2.08B | $2.82B | $2.86B | $2.87B | $2.47B | $1.61B | $2.02B | $986.2M | $612.6M | $254.5M | $149.26M | — | |
| $32M | — | — | — | — | — | $22M | $31M | $22M | $52M | $132M | $362M | $382M | $462M | $267.1M | $97.67M | $140.84M | $30.03M | $70.2M | |
| $9.94B | $8.45B | $8.08B | $7.79B | $7.67B | $7.98B | $7.35B | $8.8B | $10.76B | $8.62B | $10.24B | $8.92B | $6.21B | $6.18B | $3.4B | $2.13B | $1.29B | $639.28M | $633.07M | |
| $587M | $1.81B | $1.55B | $963M | $454M | $450M | $676M | -$203M | -$2.38B | $102M | -$566M | $1.53B | $2B | -$409.5M | $79.7M | $299.96M | -$110.09M | $181.15M | $124.11M | |
| — | 17.66% | 16.06% | 11% | 5.59% | 5.34% | 8.42% | -2.36% | -28.45% | 1.17% | -5.85% | 14.62% | 24.38% | -7.1% | 2.29% | 12.36% | -9.32% | 22.08% | 16.39% | |
| — | $3.02B | $2.81B | $2.23B | $1.85B | $2B | $2.5B | $1.87B | $435M | $2.96B | $2.3B | $3.99B | $3.62B | $1.61B | $1.07B | $912.56M | $144.42M | $330.41M | — | |
| $47M | $48M | $33M | $26M | $14M | $7M | $13M | $12M | $11M | $12M | $8M | $4M | $5M | $8M | $6M | $4.08M | $1.29M | $1.12M | $9.4M | |
| — | -$142M | -$247M | -$28M | -$35M | -$373M | -$502M | -$1.43B | $20M | $348M | -$73M | -$295M | $263M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | $293M | $5.8M | $2.1M | $22.78M | -$5.55M | $17.59M | -$4.53M | |
| -$940M | $367M | $167M | -$390M | -$129M | -$1.02B | -$934M | -$1.84B | -$4.15B | -$1.74B | -$2.44B | -$155M | $1.05B | -$1.31B | -$394.2M | -$18M | -$236.26M | $174.96M | — | |
| $285M | $247M | $239M | $221M | $83M | -$87M | -$375M | -$54M | -$10M | -$4.15B | -$27M | $133M | $174M | -$450.8M | -$278.2M | -$177.56M | -$28.07M | -$1.5M | -$73M | |
| -$1.21B | $157M | -$46M | -$592M | -$225M | -$948M | -$560M | -$1.79B | -$4.14B | $2.4B | -$2.41B | -$288M | $880M | -$863.6M | -$116M | $159.56M | $366.67M | $406.6M | $199.9M | |
| — | 1.53% | -0.48% | -6.76% | -2.77% | -11.24% | -6.98% | -20.79% | -49.45% | 27.56% | -24.89% | -2.76% | 10.72% | -14.97% | -3.33% | 6.57% | 31.04% | 49.56% | 26.4% | |
| -$17M | -$37M | -$26M | -$19M | $13M | $11M | $1M | $5M | $4M | $0 | $1M | $4M | -$1M | $2.5M | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | -$560M | -$1.79B | -$4.15B | $2.4B | -$2.41B | -$292M | $881M | -$866.1M | -$116M | $159.56M | -$208.19M | $176.46M | — | |
| -$985M | $576M | -$344M | -$417M | -$494M | -$1.08B | -$607M | -$1.74B | -$4.39B | $2.62B | -$2.98B | -$918M | $98M | -$879.5M | $44.2M | -$218.89M | -$152.93M | — | — | |
| USD/shares | — | $0.42 | -$0.13 | -$1.62 | -$0.62 | -$2.64 | -$1.58 | -$5.08 | -$11.81 | $6.86 | -$6.94 | -$0.85 | $2.63 | -$2.70 | -$0.38 | $0.52 | -$1.06 | $1.11 | $1.25 |
| USD/shares | — | $0.42 | -$0.13 | -$1.62 | -$0.62 | -$2.64 | -$1.58 | -$5.08 | -$11.81 | $6.83 | -$6.94 | -$0.85 | $2.58 | -$2.70 | -$0.38 | $0.49 | -$1.06 | $1.11 | $1.25 |
| shares | — | 370.9M | 368M | 364.9M | 362M | 358.9M | 355M | 352.1M | 351.3M | 350.2M | 347.3M | 342.7M | 335.4M | 321M | 305.4M | 304.66M | 195.81M | 158.24M | 159.73M |
| shares | — | 375M | 368M | 364.9M | 362M | 358.9M | 355M | 352.1M | 351.3M | 351.8M | 347.3M | 342.7M | 341.5M | 321M | 305.4M | 326.12M | 195.81M | 158.51M | 159.73M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2017: $1.14B in buybacks, $683.72M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Bausch Lomb | $5,101,000,000 | $4,791,000,000 | $4,146,000,000 | $3,768,000,000 | $3,765,000,000 | $3,415,000,000 | $3,778,000,000 | — |
| Salix Segment | $2,578,000,000 | $2,333,000,000 | $2,250,000,000 | $2,090,000,000 | $2,074,000,000 | $1,904,000,000 | $2,022,000,000 | $1,749,000,000 |
| International Rx | $1,132,000,000 | $1,111,000,000 | $1,071,000,000 | $988,000,000 | $1,166,000,000 | $1,181,000,000 | $1,154,000,000 | — |
| Diversified Segment | $937,000,000 | $950,000,000 | $943,000,000 | $978,000,000 | $1,121,000,000 | — | — | — |
| Solta Medical Segment | $518,000,000 | $440,000,000 | $347,000,000 | $300,000,000 | $308,000,000 | $253,000,000 | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | $4,408,000,000 | $4,739,000,000 | $4,664,000,000 |
| Diversified Products Segment | — | — | — | — | $1,121,000,000 | $1,274,000,000 | $1,087,000,000 | $1,350,000,000 |
| Ortho Dermatologics Segment | — | — | — | — | $564,000,000 | $548,000,000 | $560,000,000 | $617,000,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States and Puerto Rico | $6,138,000,000 | $5,767,000,000 | $5,194,000,000 | $4,836,000,000 | $4,887,000,000 | $4,791,000,000 | $5,164,000,000 | $5,011,000,000 |
| Other Countries | $1,153,000,000 | $1,083,000,000 | $1,011,000,000 | $887,000,000 | $1,066,000,000 | $1,112,000,000 | $995,000,000 | $1,127,000,000 |
| China | $493,000,000 | $496,000,000 | $441,000,000 | $413,000,000 | $490,000,000 | $341,000,000 | $368,000,000 | $361,000,000 |
| Canada | $417,000,000 | $402,000,000 | $366,000,000 | $351,000,000 | $343,000,000 | $331,000,000 | $339,000,000 | $319,000,000 |
| Poland | $382,000,000 | $350,000,000 | $319,000,000 | $278,000,000 | $280,000,000 | $238,000,000 | $231,000,000 | $218,000,000 |
| Mexico | $278,000,000 | $315,000,000 | $322,000,000 | $276,000,000 | $256,000,000 | $225,000,000 | $228,000,000 | $211,000,000 |
| France | $249,000,000 | $230,000,000 | $214,000,000 | $203,000,000 | $208,000,000 | $179,000,000 | $201,000,000 | $205,000,000 |
| South Korea | $234,000,000 | $146,000,000 | $93,000,000 | $77,000,000 | $76,000,000 | $68,000,000 | — | — |
| Russia | $198,000,000 | $161,000,000 | $148,000,000 | $181,000,000 | $160,000,000 | $137,000,000 | $180,000,000 | $154,000,000 |
| Japan | $192,000,000 | $188,000,000 | $194,000,000 | $200,000,000 | $230,000,000 | $226,000,000 | $241,000,000 | $226,000,000 |
| Germany | $176,000,000 | $159,000,000 | $152,000,000 | $147,000,000 | $154,000,000 | $144,000,000 | $150,000,000 | $170,000,000 |
| United Kingdom | $141,000,000 | $135,000,000 | $125,000,000 | $115,000,000 | $116,000,000 | $86,000,000 | $115,000,000 | $117,000,000 |
| Spain | $109,000,000 | $99,000,000 | $92,000,000 | $84,000,000 | $88,000,000 | $78,000,000 | $86,000,000 | $83,000,000 |
| Italy | $106,000,000 | $94,000,000 | $86,000,000 | $76,000,000 | $80,000,000 | $71,000,000 | $85,000,000 | — |
| Egypt | — | — | — | — | — | — | $218,000,000 | $178,000,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $10,156,000,000 | $9,518,000,000 | $8,663,000,000 | $8,025,000,000 | $8,328,000,000 | $7,924,000,000 | $8,489,000,000 | $8,271,000,000 |
| Pharmaceutical Products | $4,747,000,000 | $4,396,000,000 | $3,909,000,000 | $3,642,000,000 | $3,743,000,000 | $3,680,000,000 | $4,079,000,000 | $4,028,000,000 |
| Device Products | $2,439,000,000 | $2,240,000,000 | $1,997,000,000 | $1,872,000,000 | $1,903,000,000 | $1,566,000,000 | $1,717,000,000 | $1,640,000,000 |
| Over the Counter Products | $2,008,000,000 | $1,903,000,000 | $1,797,000,000 | $1,619,000,000 | $1,538,000,000 | $1,430,000,000 | $1,447,000,000 | $1,412,000,000 |
| Branded and Other Generic Products | $962,000,000 | $979,000,000 | $960,000,000 | $892,000,000 | $1,144,000,000 | $1,248,000,000 | $1,246,000,000 | $1,191,000,000 |
| Other Revenues | $110,000,000 | $107,000,000 | $94,000,000 | $99,000,000 | $106,000,000 | $103,000,000 | $112,000,000 | $109,000,000 |
| Product And Service Other | $110,000,000 | $107,000,000 | $94,000,000 | $99,000,000 | $106,000,000 | $103,000,000 | $112,000,000 | $109,000,000 |
| Price Appreciation Credit | $18,000,000 | $18,000,000 | $11,000,000 | $10,000,000 | $17,000,000 | $15,000,000 | $11,000,000 | $31,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Salix Segment | $1,925,000,000 | $1,602,000,000 | $1,548,000,000 | $1,489,000,000 | $1,493,000,000 | $1,338,000,000 | $1,349,000,000 | $1,149,000,000 |
| Bausch Lomb | $1,125,000,000 | $1,108,000,000 | $980,000,000 | $874,000,000 | $958,000,000 | $909,000,000 | $1,117,000,000 | — |
| Diversified Segment | $627,000,000 | $626,000,000 | $586,000,000 | $612,000,000 | $722,000,000 | — | — | — |
| International Rx | $334,000,000 | $376,000,000 | $335,000,000 | $324,000,000 | $403,000,000 | $386,000,000 | $352,000,000 | — |
| Solta Medical Segment | $232,000,000 | $213,000,000 | $161,000,000 | $135,000,000 | $167,000,000 | $131,000,000 | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | $1,159,000,000 | $1,332,000,000 | $1,330,000,000 |
| Diversified Products Segment | — | — | — | $612,000,000 | $722,000,000 | $814,000,000 | $801,000,000 | $1,012,000,000 |
| Ortho Dermatologics Segment | — | — | — | — | $265,000,000 | $228,000,000 | $216,000,000 | $257,000,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Bausch Lomb | 22.1% | 23.1% | 23.6% | 23.2% | 25.4% | 26.6% | 29.6% | — |
| Salix Segment | 74.7% | 68.7% | 68.8% | 71.2% | 72% | 70.3% | 66.7% | 65.7% |
| International Rx | 29.5% | 33.8% | 31.3% | 32.8% | 34.6% | 32.7% | 30.5% | — |
| Diversified Segment | 66.9% | 65.9% | 62.1% | 62.6% | 64.4% | — | — | — |
| Solta Medical Segment | 44.8% | 48.4% | 46.4% | 45% | 54.2% | 51.8% | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | 26.3% | 28.1% | 28.5% |
| Diversified Products Segment | — | — | — | — | 64.4% | 63.9% | 73.7% | 75% |
| Ortho Dermatologics Segment | — | — | — | — | 47% | 41.6% | 38.6% | 41.7% |